1Office for national statistics(ONS),cancer survival in England:patients diagnosed 2005—2009 and followed up to 2010[S].London:ONS,2011.
2Hato SV,De V,Lesterhuis WJ.Stenting the importance of immune modulation by platinum chemotherapeutics[J].Oncoimmunology,2012,1(2):234-236.
3Bookman MA,Darcy KM,Clarke-Pearson D,et al.Evaluation of monoclonal humanized anti-HER2 antibody,trastuzumab,in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2:a PhaseⅡtrial of the Gynecologic Oncology Group[J].J Clin Oncol,2003,21(2):283-290.
4Pujade-Lauraine E,Hilpert F,Weber B,et al.Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer:the AURELIA open-label randomized phaseⅢtrial[J].J Clin Oncol,2014,32(13):1302-1308.
5Aghajanian C,Blank SV,Goff BA,et al.A randomised,double-blinded,placebo-controlled,phase HI trial of chemotherapy with or without bevacizumab in patients with platinum sensitive recurrent epithelial ovarian,primary peritoneal or fallopian tube cancer[J].J Clin Oncol,2012,30(17):2039-2045.
6Patel D,Lahiji A,Patel S,et al.Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vⅢon the cell surface[J].Anticancer Res,2007,27(5 A):3355-3366.
7Lin CK,Chao TK,Yu CP,et al.The expression of six biomarkers in the four most common ovarian cancers:correlation with clinicopathological parameters[J].APMIS.2009,117(3):162-175.
8Steffensen KD,Waldstrom M,Pallisgard N,et al.Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type:the PaLiDo study,a phaseⅡnonrandomized multicenter study[J].Int J Gynecol Cancer,2013,23(1):73-80.
9McAlpine JN,Wiegand KC,Vang R,et al.HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy[J].BMC Cancer,2009,9:433.
10Gordon MS,Matei D,Aghajanian C,et al.Clinical activity of pertuzumab(rhuMAb 2C4),a HER dimerization inhibitor,in advanced ovarian cancer:potential predictive relationship with tumor HER2 activation status[J].J Clin Oncol,2006,24(26):4324-4332.
2Jing-Ting Jiang, Chang-Ping Wu, Lu-Jun Chen, Xiao Zheng, Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou 213003, Jiangsu Province, China Yi-Bei Zhu, Jing Sun, Xue-Guang Zhang, Key Laboratory of Stem Cell of Jiangsu Province, Institute of Biotechnology, Key Laboratory of Clinical Immunology of Jiangsu Province, Soochow University, Suzhou 215123, Jiangsu Province, China Yue-Ping Shen, Wen-Xiang Wei, Department of Medicine, Soochow University, Suzhou 215123, Jiangsu Province, China Bin-Feng Lu, Department of Immunology, University of Pitts- burgh School of Medicine, Pittsburgh, PA 15261, United States.Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients[J].World Journal of Gastroenterology,2010,16(48):6155-6162. 被引量：83
7Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity[J]. J Transl Med, 201 3, 11:83.
8Pievani A, Borleri G, Pende D, et al. Dual- functional capability of CD3CD56 CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity[J].Blood, 2011, 118 (12):3301-3310.
9Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors[J]. Expert Opin Biol Ther, 2012, 12(6):673-684.
10Schmidt-Wolf IG, Lefterova P, Johnston V, et al. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells[J]. Cell Immunol, 1996, 169(1 ):85-90.
